OKYO Pharma Limited (OKYO) vs Zhengye Biotechnology Holding Limited (ZYBT)
A side-by-side comparison of OKYO Pharma Limited and Zhengye Biotechnology Holding Limited across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
OKYO
OKYO Pharma Limited
$1.46HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
ZYBT
Zhengye Biotechnology Holding Limited
$1.11HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — OKYO vs ZYBT
growth of $100 · dividends reinvested · last 2yOKYO +31.2% (+14.6%/yr)ZYBT -75.5% (-50.5%/yr)OKYO compounded faster over this window
Log scale — wide-divergence pair
OKYO ZYBT
OKYO vs ZYBT: by the numbers
- •OKYO is the larger company ($56M vs $53M market cap).
- •Both run net losses; OKYO's is the smaller (0.00% vs -59.97% net margin).
Metrics side by side
Valuation
| Metric | OKYO | ZYBT |
|---|---|---|
| P/B ratio | 4.54 | 1.47 |
Profitability
| Metric | OKYO | ZYBT |
|---|---|---|
| Gross margin | 0.00% | 20.51% |
| Operating margin | 0.00% | -58.66% |
| Net margin | 0.00% | -59.97% |
| ROE | -72.55% | -27.93% |
| ROIC | -68.91% | -17.88% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.